NCT06153069 - Subclinical TB With Innovative Modified Short-course Regimens | Biotech Hunter

Enrollment

556

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

October 31, 2025

Study Completion Date

November 30, 2027

Conditions

Tuberculosis

Interventions

DRUG

Short-course regimen

"During the intensive phase (8 weeks), rifampicin ≤50kg 450 mg daily, \>50kg 600 mg daily; isoniazid 300 mg daily; pyrazinamide ≤50kg 1000mg daily, 50-70kg 1500mg daily, \>70kg 2000mg daily; ethambutol ≤50kg 750mg daily, \>50kg 1000mg daily; All treatment is taken orally.~During the continuation phase (0 or 9 weeks based on the radiological manifestations), rifampicin ≤50kg 450 mg daily, \>50kg 600 mg daily; isoniazid 300 mg daily; All treatment is taken orally."

DRUG

Standard regimen

"During the intensive phase (8 weeks), rifampicin ≤50kg 450 mg daily, \>50kg 600 mg daily; isoniazid 300 mg daily; pyrazinamide ≤50kg 1000mg daily, 50-70kg 1500mg daily, \>70kg 2000mg daily; ethambutol ≤50kg 750mg daily, \>50kg 1000mg daily; All treatment is taken orally.~During the continuation phase (18 weeks), rifampicin ≤50kg 450 mg daily, \>50kg 600 mg daily; isoniazid 300 mg daily; All treatment is taken orally."

Trial Locations (2)

200040

Huashan Hospital of Fudan University, Shanghai

Unknown

Hangzhou Red Cross Hospital, Hangzhou

All Listed Sponsors

lead

Huashan Hospital

OTHER